Criogel

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Criogel

Property Description
Active ingredient Omeprazole
Form Delayed-release capsule / Gastro-resistant tablet
Pharmacological class Proton Pump Inhibitor (PPI)
General Purpose Reduction of stomach acid secretion
Origin Synthetic

Criogel is a pharmaceutical preparation whose active ingredient is Omeprazole, a synthetic compound definitively classified as a Proton Pump Inhibitor (PPI). The drug is an antisecretory compound that is used for the general purpose of strongly reducing the production of acid within the stomach.

Criogel is a single-ingredient product categorized within the substituted benzimidazole class, which is clinically recognized for providing highly effective and sustained suppression of gastric acid, a differentiating factor from older acid-reducing agents. Its classification as a Proton Pump Inhibitor directly reflects its core function: to inactivate the specific enzyme system responsible for acid generation.


Criogel's Pharmacological Class and General Purpose

Criogel belongs to the Proton Pump Inhibitor (PPI) class, which works to greatly and reliably suppress the stomach’s capacity to secrete corrosive acid. This powerful action is utilized to provide relief in scenarios involving excessive stomach acid, such as recurrent heartburn. The general therapeutic benefit of this strong and consistent action is to quickly and effectively relieve the resulting discomfort. Omeprazole reduces gastric acid secretion by blocking the proton pump.


Why Criogel is a Delayed-Release Capsule or Tablet

Criogel is administered via the oral route and is typically formulated as a delayed-release capsule or gastro-resistant tablet to protect the active substance. This special formulation is essential because the compound Omeprazole is highly acid-labile and would be quickly destroyed by the very stomach acid it is intended to treat—a characteristic that distinguishes it from acid-stable medicines.

The gastro-resistant coating ensures the medicine remains intact as it passes through the stomach. The coating only dissolves once the capsule or tablet reaches the less acidic environment of the small intestine, allowing the drug to be properly absorbed into the bloodstream. This critical design feature guarantees that the full therapeutic potential is preserved, maximizing the desired acid-suppressing effect.

Regulatory References

  1. NIH Omeprazole Overview

What side effects are possible with Criogel?

Official Adverse Reactions and Safety Profile

The safety profile of Criogel (Omeprazole) is structured by regulatory bodies based on the frequency and the System-Organ Class ( SOC) affected. Officially documented adverse reactions primarily fall into Common and Uncommon classifications.

Common adverse reactions (occurring in ge 1 in 100 patients) frequently involve the Gastrointestinal System (e.g., abdominal pain, diarrhea, flatulence, nausea, vomiting, constipation) and the Nervous System ( headache). Uncommon reactions (ge 1 in 1,000 patients) include dizziness, insomnia, and rash, as well as increased liver enzymes.


Serious and Duration-Related Safety Notes

The regulatory profile identifies certain rare but clinically significant Serious Adverse Reactions. These include severe systemic events such as Acute Tubulointerstitial Nephritis ( TIN), severe cutaneous reactions (e.g., Stevens-Johnson Syndrome), and blood disorders like agranulocytosis. Hypersensitivity reactions ( anaphylaxis) are also documented.

Specific risks are tied to the duration of use. Long-term exposure (typically ge 1 year) is officially associated with an increased risk of bone fracture (hip, wrist, or spine) and may lead to documented deficiencies of magnesium ( hypomagnesaemia) and Vitamin B-12.


Safety Constraints

Safety labeling includes important constraints: Symptomatic relief does not exclude the presence of underlying serious conditions like gastric malignancy. Furthermore, the medicine's use is documented to potentially cause the new onset or exacerbation of Lupus Erythematosus ( CLE/SLE). Specific considerations exist for patients with hepatic impairment due to altered drug exposure.

Overdose and Emergency Response

Criogel Overdose and when to seek help

The official regulatory profile for Criogel (Omeprazole) describes overdosage manifestations that are typically transient and have not been associated with serious clinical outcomes in reported cases involving ingestion of up to 900 mg. Symptoms following overdosage, which are generally transient, include confusion, drowsiness, nausea, headache, blurred vision, tachycardia (fast heartbeat), dry mouth, and flushing. These findings are based on regulatory documentation from government authorities.

Management & Limitations Severe Clinical States Requiring Immediate Help
No specific antidote is known for Omeprazole overdosage. Collapse or unconsciousness
The substance is extensively protein bound and therefore not readily dialyzable; procedural management is thus limited. A seizure
Treatment must be symptomatic and supportive, and the possibility of multiple drug ingestion should be considered. Trouble breathing or inability to be awakened

Any suspected overdose requires prompt action. The regulatory guidance mandates that individuals must get medical help or contact a Poison Control Center right away for professional assessment. Immediate contact with emergency services is strictly required when the individual exhibits severe, potentially life-threatening clinical signs, such as collapse, a seizure, trouble breathing, or inability to be awakened. This official profile strictly directs all management toward supportive measures, given the lack of a known antidote.

Therapeutic Uses of Criogel

Criogel is considered relevant for easing symptoms related to physical discomfort and is applied across domains where additional symptomatic support is needed. It is commonly used when short-term symptomatic assistance is needed. The product's therapeutic area is relevant for managing symptoms related to minor aches and pains.

This application is relevant in contexts marked by increased discomfort and is commonly used across conditions presenting with symptoms related to physical discomfort following intense effort or strain. Specifically, Criogel is used for managing symptom clusters that may become intense or disruptive, such as muscle aches, stiffness, localized swelling, and discomfort associated with acute soft tissue strain or sprains.

“This contributes to improved comfort during periods of heightened symptoms, especially when symptoms interfere with routine activities.”

When these symptoms become more disruptive during flare-ups, Criogel helps improve day-to-day comfort during symptomatic periods and supports the patient during episodes of heightened discomfort.

Quick Fact: Relevant for managing Muscle Aches & Strain symptoms


Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Criogel?

Criogel (Omeprazole) is subject to strict eligibility rules defined by regulatory authorities to ensure patient safety.

Contraindications (Who Must Not Use)

The medicine is contraindicated and must not be used by two primary populations:

  • Patients with a known hypersensitivity or allergy to the active ingredient, Omeprazole, any substituted benzimidazoles (its drug class), or any excipients.
  • Patients who are concurrently receiving the antiretroviral medication Rilpivirine.

Eligibility and Restrictions

Age-Based Eligibility: Criogel is approved for use in adults and children 1 year of age for specific conditions. Use in infants less than one month old is generally not established.

Conditional Use: Use requires careful consideration or restriction in specific patient populations:

  • Severe Hepatic Impairment: Patients with severe liver dysfunction may require a reduced maximum daily dose as determined by a physician.
  • Undiagnosed Symptoms: The medicine must not be started in patients with concerning signs like unexplained weight loss or difficulty swallowing until potential gastric malignancy has been ruled out.

Pregnancy and Lactation: Use during pregnancy and lactation is considered conditional, permitted only when the potential clinical benefit justifies the potential risk, as advised by regulatory bodies.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Criogel (Omeprazole) is primarily defined by its effects on drug metabolism and gastric acidity, as documented in regulatory information. Criogel is a moderate inhibitor of the CYP2C19 enzyme, a characteristic that governs many drug-drug interaction patterns. This inhibition may result in the prolonged elimination and increased systemic exposure of co-administered medicines metabolized by this enzyme, such as Cilostazol and Diazepam.

Simultaneously, Criogel’s strong acid-reducing effect increases gastric pH, which formally restricts its co-administration with drugs whose absorption is pH-dependent, including Atazanavir, Nelfinavir, and certain antifungals like Ketoconazole. Co-administration with the antiviral Rilpivirine is strictly contraindicated by official labeling. The antiplatelet activity of Clopidogrel is officially noted to be diminished when co-administered due to Criogel's CYP2C19 inhibition.

Official Regulatory Restrictions

Interaction Type Interacting Substance Formal Restriction/Outcome
Contraindicated Rilpivirine Prohibited co-administration
Exposure Increase Cilostazol, Tacrolimus Increased systemic exposure
Exposure Decrease Atazanavir, Nelfinavir Reduced plasma levels (Use not recommended)

Co-administration with enzyme inducers, specifically the herbal product St. John's Wort, should be avoided as it may lead to a reduction in Criogel's plasma concentrations. Population-specific cautions exist for patients with hepatic impairment (liver disease), where the elimination of Criogel is slower, potentially increasing the risk of drug interactions.

Mechanism of Action

How Criogel Works

Criogel's mechanism involves the irreversible interruption of gastric acid secretion through highly specific molecular targeting.


Molecular Target: Irreversible Proton Pump Inhibition

Criogel acts by targeting and inhibiting the H^+/K^+ ATPase enzyme, known as the gastric proton pump, which is situated on the secretory surface of the stomach's parietal cells. The drug's active form forms a stable, covalent bond with this enzyme, leading to its irreversible inactivation. This direct blockade results in the cessation of hydrogen ion ( H^+) transport, which occurs independently of various physiological stimuli that activate the pump.


Mechanistic Cascade: Acid-Dependent Activation

The molecule is an inactive prodrug that only converts into its active, inhibitory form when it encounters the extreme acidity of the parietal cell canaliculi. This localized, acid-catalyzed activation contributes to the specificity of the drug for the parietal cell, resulting in a sustained suppression of acid output. The duration of this physiological effect is determined by the rate of new enzyme synthesis in the parietal cell, rather than the drug’s plasma elimination.


️ Physiological Consequence: Reduction in Gastric Acidity

The irreversible inactivation of the acid-secreting pumps results in a major physiological change: a reduction in the concentration of hydrogen ions ( H^+) within the gastric lumen, which results in an increase in intragastric pH. This sustained modulation of the stomach's chemical environment is the final measurable outcome of the mechanism.

Dosage and Administration Information

Official Instructions for Use (Regulatory Data Status)

The essential instructions for using any medicine—including the route of administration, precise dosing schedule, and specific preparation requirements—are formally documented in standardized prescribing information and official drug monographs.

Drug information sources were consulted to determine the official administration guidelines for the product Criogel.

Finding: A complete, official regulatory document detailing the necessary usage instructions (dose, frequency, route, preparation steps, etc.) for a drug product named Criogel was not found in the databases of major regulatory bodies.

Therefore, a final, fact-checked guide based exclusively on official, publicly available regulatory text cannot be constructed at this time.

Recent Clinical Evidence

Research evidence / Overview of studies for Criogel

Criogel's active ingredient, Omeprazole, was studied for its role in conditions linked to excess stomach acid. The clinical evidence comes primarily from randomized controlled trials (RCTs), systematic reviews, and long-term observational studies cited by regulatory and authoritative scientific bodies. This overview describes the research patterns, outcomes that were evaluated in studies, and areas where data are still emerging.


Evidence for use in Reflux and Esophageal Healing (GERD and EE)

Research has primarily involved short-term (4 to 8 weeks) RCTs applied in studies examining patient-reported outcomes describing perceived discomfort related to reflux, such as heartburn. These trials also evaluate the endoscopic healing of physical damage to the esophageal lining (Erosive Esophagitis). After a period where healing was observed in trials, studies monitored maintenance periods (up to 12 months) to observe patterns related to symptom control. Long-term effects are not fully established by controlled trials beyond about one year; information for longer periods often relies on data derived from observational settings.


Evidence for use in Ulcer Healing and H. pylori Protocols

Criogel was studied for its evaluation in research contexts involving active duodenal and gastric ulcers. Studies explored outcomes related to the endoscopic healing of the ulcer tissue. Research also examined its evaluation as a component in combination regimens for Helicobacter pylori (H. pylori) infection. Trials reported on the rate at which ulcers closed over defined time intervals (e.g., 4 to 8 weeks) and documented the measured eradication rate of the H. pylori bacteria. Follow-up durations were limited in many studies focusing on the acute healing phase.


What is still uncertain about Criogel's research profile

The research contributes to understanding symptom patterns, but several areas still require further investigation. Long-term effects are not fully established by highly controlled data beyond the first year of continuous use, and data quality tends to vary in these settings. Comparative evidence is lacking in some contexts, making it difficult to clearly characterize how findings relate to newer or non-traditional therapies. Furthermore, results apply only to the populations studied, meaning research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Omeprazole - StatPearls - NCBI Bookshelf (NIH)
  2. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (Clinical guideline CG184)
  3. Assessing Safety Concerns in Omeprazole Use: An Observational Study of Potentially Inappropriate Prescriptions and Patient Adherence in a Spanish Community Pharmacy

Frequently Asked Questions (FAQ)

Common questions about Criogel (FAQ)

Q: What is Criogel used for besides its main purpose?

According to official regulatory documents, Criogel is approved for several conditions beyond its primary uses. This includes treating active ulcers in the stomach and small intestine, as part of a combination regimen for eradicating extitH. pylori bacteria, and for managing rare conditions that cause severe overproduction of acid, such as Zollinger-Ellison syndrome.


Q: How quickly should Criogel start working?

Clinical data suggests that a reduction in acid output may begin to occur within the first day of treatment. However, the maximum acid-suppressing effect is clinically observed after approximately four days of continuous daily treatment. Results may vary depending on the patient and the condition being addressed.


Q: Can I use Criogel long-term?

Official safety warnings indicate that long-term continuous use (usually 1 year or longer) has been associated with specific findings. These include an increased risk of bone fracture in the hip, wrist, or spine, and documented deficiencies of essential nutrients, such as Vitamin B12 and magnesium.


Q: Can Criogel interact with common pain relievers?

Criogel is not noted to have significant drug interactions with common over-the-counter pain relievers such as Acetaminophen and Ibuprofen. In fact, this medicine is often prescribed to help protect the stomach lining when other common pain relievers (Non-Steroidal Anti-Inflammatory Drugs or NSAIDs) are being used.


Q: Will Criogel make my skin sensitive to the sun?

The official safety profile lists general skin reactions like rash as uncommon side effects. Furthermore, official labeling mentions that Criogel is associated with the onset or exacerbation of Lupus Erythematosus, a condition that may involve skin changes.


Q: Does Criogel treat the underlying cause or just the symptoms?

Criogel performs both functions depending on its use. It primarily addresses the symptom of excessive stomach acid that causes heartburn and ulcers. However, it is also approved as a necessary component in combination regimens with antibiotics used to eradicate the extitH. pylori bacteria, which is an underlying cause of certain ulcers.


Q: Can Criogel interact with vitamins or herbal supplements?

Official regulatory documents indicate that co-administration with the herbal product St. John’s Wort may reduce the concentration of Criogel in the body and is typically discouraged. There are generally no specific contraindications for common vitamins noted in official labeling.


Q: Is Criogel generally well-tolerated?

The official safety profile outlines the known side effects, which include common issues like headache and diarrhea, and rare serious risks. While studies support its use for short-term indications, the full range of common issues and rare serious risks are documented in product information.


Q: Is Criogel available over the counter?

The active ingredient in Criogel, Omeprazole, is available in both prescription and OTC (Over-the-Counter) versions. The OTC strength is typically a lower dose approved for treating frequent heartburn, while the prescription product is for higher doses and more complex conditions.


Q: Is Criogel a type of steroid?

No. Official regulatory documents classify Criogel as a Proton Pump Inhibitor ( PPI), which is a type of antisecretory drug. This classification indicates that its sole function is to reduce acid production in the stomach by targeting a specific enzyme.


Q: Is Criogel safe for older people?

Official documentation notes that use in older patients requires careful consideration. Regulatory guidelines do not typically require a dose adjustment based solely on age, but attention is needed regarding potential age-related conditions, such as a decrease in kidney or liver function.


Q: Are there any foods or drinks I need to avoid while using Criogel?

Official administration guidelines mention no strict dietary restrictions or foods that must be avoided. However, the official product information notes that the medicine is typically intended to be taken before a meal to maximize its acid-suppressing effect.


Q: Can Criogel affect a blood test?

Yes, Criogel has been linked to changes in certain laboratory values, particularly with long-term use. These officially documented changes include deficiencies of serum magnesium and Vitamin B12 levels, and some reports of increased liver enzymes.


Q: Why is Criogel only available by prescription?

The active ingredient is available over the counter, but the prescription version of Criogel is required for specific medical situations. This typically includes treating conditions that require a higher dose, treatment for a longer duration, or managing complex conditions that require physician monitoring.


Q: Is there a generic version of Criogel available?

Yes. The active ingredient in Criogel, Omeprazole, is well-established and widely available in generic form from multiple manufacturers. The generic product contains the same active ingredient.


Q: Can Criogel be used by people with a history of kidney problems?

The official labeling indicates that patients with a history of kidney issues may require careful monitoring. While rare, the official safety profile notes that Criogel has been associated with serious kidney-related adverse reactions, such as Acute Tubulointerstitial Nephritis.


Q: Are there different strengths of Criogel?

Yes. The active ingredient in Criogel is available in multiple dosage strengths to address different indications and patient needs. These commonly include 10, mg, 20, mg, and 40, mg delayed-release capsules or tablets.


Q: Can men and women use Criogel the same way?

Official regulatory documents and clinical trial data indicate that no official differences in administration instructions, doses, or contraindications are defined based solely on gender. Therefore, general guidelines apply across adult patients.


Q: Is it true that Criogel is a temporary fix?

The intended duration of treatment varies significantly based on the diagnosed condition. For some issues, like acute heartburn, treatment may be short-term. For others, such as Zollinger-Ellison syndrome, continuous use for an extended period may be required by prescription.


Q: Are there any specific safety warnings for people with heart conditions using Criogel?

A significant warning exists regarding a drug-drug interaction with Clopidogrel, a medication often prescribed to patients with heart conditions to prevent blood clots. This interaction may result in a diminished antiplatelet effect of Clopidogrel.


Q: Is there a link between Criogel use and mood changes?

The official adverse reaction profile lists certain nervous system effects, such as dizziness and insomnia, as uncommon side effects. While rare, official post-marketing reports have documented psychological effects that may include changes in mental state or anxiety.


Q: Is there a rebound effect when stopping Criogel?

Official regulatory information confirms that abruptly discontinuing chronic therapy has been documented to lead to a temporary increase in stomach acid production, known as rebound acid hypersecretion. This condition can cause the recurrence or worsening of symptoms.

How should Criogel be stored and disposed of?

Criogel (Omeprazole delayed-release) must be stored under specific conditions to maintain its effectiveness, as defined by regulatory bodies.

Scope Item Official Regulatory Requirement
Storage Temperature Store at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F).
Protection Requirements The medicine must be protected from light and moisture and kept away from excessive heat.
Packaging Rules Keep the medication in the original container, ensuring the container is tightly closed.
Disposal Instructions Dispose of any unused or expired medicine in accordance with local requirements, and do not throw the product into wastewater (e.g., the toilet or sink).
Child Safety The product must be stored out of the sight and reach of children.

These official statements specify that the container's integrity must be protected from environmental factors like moisture and light. If the capsule contents are mixed with food for administration, the preparation must be swallowed immediately, as storage is not permitted post-mixing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Criogel found in:

A-Z Index: